Interventional Medical Leader Vymed Medical Secures Tens of Millions in Series C Funding, HAOYUE CAPITAL Acts as Exclusive Financial Advisor

Recently, VCBeat learned thatBeijing WeMed Medical Equipment Co., Ltd. (hereinafter referred to as “WeMed”) has secured tens of millions of yuan in Series C financing. The round was led by Luxin Venture Capital, with participation from Wuxi Financial Investment Group, Dynamic Balance Investment, and Yifeng Capital. Haoyue Capital served as the exclusive financial advisor.。

WeMed has received investments from several renowned investment firms, including Huagai Capital, Sharing Investment, Northern Light Venture Capital, Joincare Medical Fund, and Yuanyi Capital.The proceeds from this round of financing will be used for the clinical promotion of high-end intelligent digital subtraction angiography (DSA) systems and surgical C-arms following regulatory approval, while also accelerating the R&D of products such as interventional robots.。

WeMed, established in 2014, is a Chinese medical enterprise specializing in interventional diagnosis and treatment equipment (DSA) and solutions. With years of experience in the R&D, design, and industrialization of digital vascular imaging products, the company offers a comprehensive portfolio of interventional product lines, including large-scale Digital Subtraction Angiography (DSA) systems, mobile angiography units (mid-C-arm), surgical C-arms (small C-arm), and interventional robots. Through overseas mergers and acquisitions and other strategies, WeMed has achieved an international strategic layout encompassing product R&D, manufacturing, and marketing, striving to become a leading provider of interventional diagnostic and therapeutic solutions in China.

WeMed brings together core R&D personnel from numerous renowned medical enterprises both in China and abroad. The company has established strategic partnerships with leading domestic universities and medical institutions. Grounded in the fundamental needs of frontline interventional users, WeMed provides high-quality products that meet the demands of diagnostic examinations, minimally invasive treatments, and teaching demonstrations. By continuously optimizing and upgrading its offerings, WeMed is committed to delivering user-friendly, practical, and professional interventional products.

Since its establishment, WeMed has accumulated a portfolio of core technical patents, including more than 30 authorized patent technologies covering core product technologies such as digital subtraction imaging.The company has developed digital subtraction angiography (DSA) interventional therapy equipment for clinical cardiovascular and cerebrovascular surgeries, breaking the monopoly of the international market and reducing the cost of the original multi-million-yuan instruments by nearly half. Mass production and market launch are expected in 2020.。

A review of the major global manufacturers of DSA systems reveals key players such as GE, Philips, Siemens, and Toshiba, with these imported brands accounting for over 90% of the domestic market share.

In a market where whole-system prices reach millions of yuan, with some imported models exceeding ten million yuan per unit, WeMed, as a domestic high-end interventional medical brand, has independently developed the Aurora Intelligent 7-Axis Flat-Panel DSA (Large C-arm). This system features advanced technology and superior performance, achieving clinical application standards on par with high-end international counterparts, while being priced significantly lower than imported brands.

Currently, the company’s interventional product lines have been deployed for trial and clinical use at renowned Grade IIIA hospitals—including Beijing Tiantan Hospital, the First Affiliated Hospital of Zhengzhou University, the First Affiliated Hospital of Dalian Medical University, Zhengzhou Central Hospital, and the Affiliated Hospital of Hebei University—as well as at secondary hospitals. Clinicians have consistently reported that these interventional products match or even surpass imported brands in technical capabilities and performance, enabling Digital Subtraction Angiography (DSA) systems to achieve genuine import substitution.。

In addition to continuously upgrading and optimizing the hardware and software of its product lines, WeMed has fully committed R&D resources to the field of interventional robotics, with each product actively advancing departmental development and the optimization and refinement of solutions. In the 5G era, WeMed will accelerate in-depth R&D of products and solutions in the interventional field, deeply integrating interventional diagnostic imaging with surgical robotic operations.

As the first company to propose the aforementioned integrated solution, WeMed believes that the greatest value of merging interventional robotics with DSA technology lies in enabling physicians to perform surgeries without wearing heavy lead aprons, thereby avoiding excessive radiation exposure during emergency procedures and safeguarding their own health. Siemens’ $1.1 billion acquisition of the interventional robotics company Corindus this August, which aims to integrate DSA with interventional robotics, serves precisely this purpose.

Yang He, General Manager of WeMed“The current round of financing presented numerous challenges amid the tightening pressure of the broader capital market. Throughout the entire process, the Haoyue project team leveraged its professional industrial perspective and financial background, demonstrating exceptional communication and coordination skills at every stage. Facing the arduous task of optimizing the equity structure to successfully close the financing, we are grateful to have such a capable partner. This achievement would not have been possible without the tremendous support from both existing and new shareholders. The momentum generated during this ‘capital winter’ will propel WeMed toward leapfrog development.”

Chen Lei, Deputy General Manager of Luxin Venture CapitalIt stated: “As the first listed company in China’s capital market with venture capital as its core business, Luxin Venture Capital has been actively promoting the development of outstanding domestic technological innovation enterprises. In our investments within the biotechnology industry, high-end medical devices, represented by large-scale imaging equipment, have always been a key focus of our strategic layout. In recent years, interventional medicine in China, as an emerging discipline integrating imaging diagnosis and clinical treatment, has developed rapidly and has become a clinical specialty standing on equal footing with traditional internal medicine and surgery. As essential imaging navigation equipment for interventional procedures, the ownership rate of Digital Subtraction Angiography (DSA) machines in China still lags significantly behind that of developed countries in Europe and the United States. We believe that with the development of the interventional medicine industry, DSA will have substantial growth potential in the future. The WeMed team, represented by Mr. Yang He, possesses solid R&D capabilities and extensive industry experience. The company’s seven-axis intelligent DSA is the first domestically produced DSA device in China whose performance truly rivals mid-to-high-end products from ‘GPS’ (GE, Philips, and Siemens). We believe that upon its market launch, this product will serve as a leader among domestic DSA systems, gradually breaking the import monopoly in this field. WeMed will be a crucial component of Luxin Venture Capital’s strategic layout in the field of interventional imaging. In the future, we will continue to work closely with WeMed to promote the development of China’s interventional medicine industry.”

Fu Jianping, Partner at Dongpingheng Capital“WeMed’s high-end large C-arm product successfully completed its clinical trials over the past year and is expected to obtain registration approval in the near future. This will break the monopoly held by imported products in this field and promote the development of China’s interventional medical industry. The company’s European subsidiary has established mature product offerings and sales channels, which, combined with its domestic operations, have enabled a global layout. As WeMed’s product portfolio continues to expand, customers will have more choices.”

Dr. Luo Fayong, Managing Director at Yifeng CapitalYifeng Capital stated, “We attach great importance to our strategic layout in the field of interventional therapy, with Digital Subtraction Angiography (DSA) X-ray systems serving as the core of interventional medicine. WeMed possesses industry-leading technologies and products in this domain, demonstrating strong competitiveness against traditional European and American brands. With the Chinese government gradually relaxing procurement restrictions on large-scale medical equipment for hospitals, coupled with the broader trend of domestic substitution for imported medical devices, we are optimistic about the future sales performance of WeMed’s products. Furthermore, Yifeng Capital will strategically invest across the upstream and downstream segments of the interventional therapy supply chain around WeMed to better empower its growth.”

Yang Zhenjun, Vice President of Haoyue CapitalIt stated: “Currently, the Chinese government has frequently introduced policies to reduce the prices of medical devices and high-value consumables, presenting a prime opportunity for domestic substitution in industries long dominated by imports. The DSA (Digital Subtraction Angiography) equipment sector has been monopolized by imported brands for an extended period. As one of the few Chinese manufacturers of DSA equipment, WeMed offers performance that rivals and, in some aspects, surpasses international brands, while also achieving significant breakthroughs and advantages in product registration and clinical collaborations. With the relaxation of licensing requirements for DSA equipment configuration, substantial market demand is being unleashed. We believe WeMed is well-positioned to leverage this policy momentum to accelerate its adoption in clinical settings. Notably, WeMed’s breakthroughs in interventional robotics further solidify its standing in the interventional medicine field. Haoyue Capital closely monitors innovative healthcare enterprises, dedicated to serving top-tier Chinese companies across various specialized sectors and contributing to the development of China’s healthcare industry.”